A table of U.S. approved PD1- or PDL1- inhibitors for cancer.
Note: For Tecentriq, Bavencio and Jemperli, sales were converted from reported currency using average exchange rates shared in annual reports by the relevant company.
Chart: Jon Gardner, Ned Pagliarulo / BioPharma DiveSource: FDA, companiesCreated with Datawrapper